Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Current Concepts in the Use of Small-Particle Hyaluronic Acid

Bertucci, Vince MD, FRCPC; Lynde, Carrie B. MD, FRCPC

Plastic and Reconstructive Surgery: November 2015 - Volume 136 - Issue 5S - p 132S–138S
doi: 10.1097/PRS.0000000000001834
Fillers: Original Articles

Background: Soft-tissue augmentation with hyaluronic acid (HA) fillers has become one of the most popular cosmetic procedures performed. HA fillers represent safe and commonly used fillers. Several different HA fillers are available. The differences lie in the manufacturing process, allowing for tailored uses. A small-particle HA with lidocaine (SP-HAL; Restylane Silk; Galderma, Uppsala, Sweden) was approved by the US Food and Drug Administration in June 2014 but has been available for many years in Canada as Restylane Fine Lines and in Europe as Restylane Vital.

Methods: Relevant articles were reviewed relating to the composition, effectiveness, and safety of SP-HAL. We also discuss the author’s extensive clinical experience in the use of this product in Canada.

Results: SP-HAL has demonstrated proven benefits for lip fullness, augmentation, and treatment of perioral rhytides. Although off-label in the United States, SP-HAL is also well suited for the treatment of superficial fine lines, including periorbital, forehead, marionette, and smile lines. In addition, it has also been used in the tear trough region. A novel application for SP-HAL includes use as a skinbooster with intradermal micropuncture. In this technique, small aliquots of product are injected so as to gradually rejuvenate the skin in areas such as the face and hands. Side effects of SP-HAL were generally transient and mild. The most common side effects were swelling, tenderness, bruising, pain, and redness.

Conclusion: SP-HAL is an effective and safe HA filler with varied clinical uses.

Toronto, Ontario, Canada

From the Division of Dermatology, University of Toronto.

Received for publication April 3, 2015; accepted June 25, 2015.

Disclosure: Dr. Bertucci has been an investigator, speaker, and consultant for Allergan, Galderma, Merz, and Valeant. Dr. Lynde has no financial interest in any of the products, devices, or drugs mentioned in this article.

Vince Bertucci, MD, FRCPC, Division of Dermatology, University of Toronto, 8333 Weston Road, Suite 100, Woodbridge, Ontario L4L 8E2, Canada, vince.bertucci@utoronto.ca

©2015American Society of Plastic Surgeons